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My mitochondria comprise a very large proportion of me. I cannot do the calculation, but I suppose there is almost as much of
them in sheer dry bulk as there is the rest of me. Looked at in this way, I could be taken for a very large, motile colony of
respiring bacteria, operating a complex system of nuclei, microtubules, and neurons for the pleasure and sustenance of their
families, and running, at the moment, a typewriter.
Lewis Thomas, The Lives of a Cell: Notes of a Biology Watcher
In “The Lives of a Cell”, L. Thomas restated a
hitherto prosaic observation as a profound
conjecture, i.e, that mitochondria - the earliest
aerobic bacteria - may have “created” us as a
‘symbiont utilitarian layer’ for their survival.
The same can be argued for the bacteria
resident in the gastrointestinal system which, to
put it bluntly, may have ‘created’ us in order to
feed them. There are more bacteria in the
human body (>500 species) than there are
human cells. Most of these reside in the gut and
the majority (> 90%) belong to two phyla, the
Firmicutes (which include Clostridium, Strepto-
coccus and Staphylococcus), and the Bacteroidetes
(which include Flavobacterium). Aside from the
sobering philosophical issues about ‘free will’
that such a scenario raises (separately from
quantum mechanics), it seems logically
imperative that the colonization of the human
body by bacteria, or the colonization of human
cells on bacteria, must be inextricably
intertwined with regard to the survival of the
two symbionts.
Recent and emerging research implicates the
commensal micro-organisms residing in the
gut, the gut microbiota, in a variety of
dysfunctional biological processes, ranging
from obesity to autoimmune disorders. With
the advent of germ free (GF) murine models,
unequivocal correlations have been found
between the presence of specific species of
bacteria with disease biomarkers and
symptoms. The chain of causation leads to
small molecules that the gut microbiota
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ingredients or macromolecular excipients such
as fiber, gums and cellulosic derivatives.
Fermentation of these macromolecular food or
pharmaceutical excipient ingredients by the gut
microbiota leads to the formation of short
chain fatty acids (SCFA) which can be absorbed
from the gut into the general circulation. It
turns out that the magnitude and proportion of
the three major SCFAs’, i.e acetate (C2),
propionate (C3) and butyrate (C4), are
dependent on the type and quantity of
macromolecular food or pharmaceutical
ingredients ingested, on the ratio of
f e r m e n t a b l e  t o  n o n - f e r m e n t a b l e
macromolecular species and on the
composition of the phyla and species of gut
microbes. The latter is itself influenced by the
food and pharmaceutical ingredients (both
absorbable and non-absorbable) ingested (as an
example, antibiotics are notorious for causing
intestinal de-population of commensal bacteria
while probiotics and yogurt can repopulate
select species). Diet has been shown to alter the
human gut microbiome.
Gut microbiota SCFA products can regulate
immune homeostasis. SCFA can promote T cell
differentiation into effector or regulatory T cells
in a cytokine dependent manner thereby
regulating adaptive immunity and immune
tolerance. In a GF murine model, the
introduction of a specific bacterium in the gut
was shown to induce autoimmune arthritis via
the T-helper cell production of autoantibodies.
The increased intestinal permeability caused by
altered phylogenetic gut microbiota can cause
metabolic endotoxemia; an increase in
lipopolysaccharide (LPS) blood concentration.
Endotoxemia can contribute to low-grade
inflammation, insulin resistance and adipocyte
hyperplasia that characterize the metabolic
syndrome. SCFA act as signal transduction
molecules via G-protein coupled receptors and
as epigenetic regulators of gene expression by
modulating histone deacetylases (HDAC). The
phylogenetic composition of gut microbiota has
been shown to differ between obese and lean
humans with consequent differences in colonic
fermentation patterns and SCFA concentration
and composition that, in turn, are correlated
with energy extraction and regulation. Colonic
acetate has been demonstrated to cross the
blood brain barrier and is associated with
changes in the expression profiles of regulatory
neuropeptides that favor appetite suppression.
At human equivalent dosages of the order of
grams per day, HPMC was shown to
significantly decrease cholesterol levels in
hypercholesterolemic individuals on statin
therapy and improve glucose homeostasis and
leptin levels in a diet induced obesity mouse
model. Hence, at a maximum reported oral
concentration of 670 mg in the FDA, IID
database, or ingesting capsules made from
HPMC (~150 mg, twice daily), HPMC content
in prophylactic medicinal products is within 1
order of magnitude of that required to alter gut
microbiota composition or glucose and lipid
homeostasis; its biological effect is hence
significant. Studies with diet suplemented,
fermentable carbohydrates (acacia gum, high
amylose starch, partially hydrolyzed guar gum,
pectin) in a range of 10 grams through 108
grams once daily have demonstrated biological
effects ranging from a reduction of cholesterol,
increasing insulin sensitivity, weight reduction
and decreased cytotoxicity of the fecal aqueous
phase, that were attributed to an increase in the
colonic SCFA levels. There is extensive
experimental and clinical trial data to suggest
that dietary inulin may counteract the effects of
carcinogens, via production of anti-proliferative
short-chain fatty acids formed by bacterial
fermentation of inulin in the gut.
Pharmaceutical dosage forms contain various
macromolecular, partially or incompletely
digestible excipients such as cellulose esters or
ethers, starches and gums that may be
fermented in the colon. When consumed orally
as a prophylactic treatment, these excipients can
alter colonic SCFA concentration and
composition, in addition to altering the
enterohepatic pools. Pharmaceutical scientists
must become cognizant of the fact that the
magnitude or the ratios of cellulose acetate,
cellulose acetate butyrate and cellulose acetate




propionate in prophylactic sustained release
dosage forms alters, not only the API release
profile and ADME, but also a myriad of SCFA
activated downstream effectors that are
dependent on the mass and/or mass ratios of
these ingredients in the formulation.
Considering that SCFA is implicated in a wide
spectrum of biological effects, it would be
prudent to ensure that the biological effects of
such macromolecular excipients do not
superimpose on those of the API, and if they
do, the extent of those effects is either known
or can be estimated prior to beginning clinical
trials.  
Conventional wisdom has long held that
because macromolecular excipients are not
absorbed into the bloodstream, they do not
exert any biological effects. But then again, for
a period of time lasting for more than 2000
years, conventional wisdom accepted the
Ptolemiac geocentric model of the universe as
the truth. Not only do ‘small molecule’
pharmaceutical excipients exhibit biological
activity; orally administered macromolecular
excipients do so as well.
This Journal is © IPEC-Americas Inc March 2016 J. Excipients and Food Chem. 7 (1) 2016 -  3
DOWNLOAD FREE FROM HTTP://OJS.ABO.FI/JEFC
This material MAY NOT be used for commercial purposes
see Creative Commons Attribution NonCommercial‐NoDerivatives 4.0 International
